**Timeline of Advisory Committee on Immunization Practices (ACIP) recommendations for diphtheria and tetanus toxoids and acellular pertussis vaccines (DTaP) and tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap), 1991 – 2015**

**1991**: The first DTaP product (Acel-Imune) was licensed by the Food and Drug Administration (FDA) and recommended by ACIP for use in place of diphtheria and tetanus toxoids and whole-cell pertussis (DTP) for the fourth and fifth doses of the recommended DTP series among children ≥ 15 months of age. (*1*)

**1992**: FDA licensed a second DTaP vaccine product (Tripedia) for use as the fourth and/or fifth dose of the recommended DTP series. (*2*)

**1996**: FDA licensed several DTaP vaccine products for the recommended diphtheria, tetanus and pertussis vaccination series among children aged 6 weeks–6 years: Acel-Imune for all five doses; Tripedia for the first four doses; TriHIBit for the fourth dose. (*3*)

**1997**: FDA licensed one DTaP vaccine product (Infanrix) for the initial four doses of the recommended diphtheria, tetanus, and pertussis vaccination series among children aged 6 weeks–6 years. (*3*)

**1997**: ACIP recommended DTaP vaccines for all five doses in the childhood vaccination schedule. (*3*)

**2002**: FDA approved the expanded use of one DTaP vaccine product (Daptacel) for the first 4 doses among infants and children aged 6 weeks–6 years. The FDA licensed a combined DTaP, hepatitis B (HepB) (recombinant) and inactivated poliovirus vaccine (IPV), DTaP-HepB-IPV (Pediarix) for use in infants for the first three doses at ages 2, 4, and 6 months. (*4,5*)

**2003:** FDA approved the expanded use of one DTaP vaccine product (Infanrix) as a fifth dose for children aged 4–6 years. (*6*)

**2005**: FDA licensed two Tdap vaccine products for a single dose: Adacel (aged 11 through 64 years) and Boostrix (aged 10–18 years). ACIP recommend a single dose of Tdap to replace a dose of tetanus and diphtheria toxoids vaccine (Td) for adolescents (aged 11–18 years) and adults (aged 19–64 years). (*7,8*)

**2008**: FDA licensed two DTaP vaccine products: a combined DTaP, inactivated poliovirus vaccine (IPV), and *Haemophilus influenzae* type b conjugate (Hib) vaccine product (DTaP-IPV/Hib) (Pentacel) for the initial four doses; combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP) and inactivated poliovirus (IPV) vaccine, DTaP-IPV (Kinrix) for the fifth dose of the DTaP vaccine series. FDA approved expanded use of Boostrix (Tdap) for use in persons aged 10–64 years. (*9-11*)

**2010**: ACIP recommended 1) Tdap should be administered regardless of interval since the last tetanus- or diphtheria-toxoid containing vaccine, 2) adults aged ≥ 65 years who have or anticipate having close contact with an infant aged < 12 months should receive a single dose of Tdap, and other adults aged ≥ 65 years may be given a single dose of Tdap, and 3) children aged 7–10 years not fully vaccinated against pertussis and for whom no contraindication to pertussis vaccine exists should receive a single dose of Tdap. (*12*)

**2011**: ACIP recommended 1) health care personnel, regardless of age, should receive a single dose of Tdap as soon as feasible if they have not previously received Tdap, and 2) pregnant women who have not previously received Tdap should receive a dose of Tdap during pregnancy, preferably during the third or late second trimester; if not administered during pregnancy, Tdap should be administered immediately postpartum. FDA approved expanded use of Boostrix (Tdap) for use in persons aged ≥ 10 years. (*13-15*)

**2012**: ACIP recommended 1) all adults aged ≥ 19 years who have not yet received a dose of Tdap should receive a single dose, and 2) pregnant women should receive a dose of Tdap during each pregnancy, irrespective of the patient’s prior history of receiving Tdap. (*16,17*)

**2014**: FDA approved to lower the age indication for Adacel (Tdap) administration from 11 to 10 years. (*18*)

**2015**: FDA licensed a combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP) and inactivated poliovirus (IPV) vaccine, DTaP-IPV (Quadracel) for the fifth dose of the DTaP vaccine series. (*19*)

**References**

1. CDC. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use – supplementary ACIP statement. MMWR Recomm Rep 1992;41(No. RR-1):1-10.
2. CDC. Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series – Update to the supplementary ACIP statement. MMWR Recomm Rep 1992;41(No. RR-15):1-5.
3. CDC. Pertussis Vaccination: Use of acellular pertussis vaccines among infants and young children. MMWR Recomm Rep 1997;46(No. RR-7):1-25.
4. CDC. Notice to Readers: Food and Drug Administration approval of a fifth acellular pertussis vaccine for use among infants and young Children --- United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:574.
5. CDC. Notice to Readers: FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX™) for use in infants. MMWR Morb Mortal Wkly Rep 2003;52:203-4.
6. CDC. Notice to Readers: FDA approval of diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, (INFANRIX®) for fifth consecutive DTaP vaccine dose. MMWR Morb Mortal Wkly Rep 2003;52;921.
7. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(No. RR-3):1-34.
8. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006;55(No. RR-17):1-37.
9. CDC. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and *Haemophilus* b conjugate vaccine and guidance for use in infants and children. MMWR Morb Mortal Wkly Rep 2008;57;1079-80.
10. CDC. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR Morb Mortal Wkly Rep 2008; 57:1078-9.
11. CDC. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep 2009;58;374-5.
12. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011;60;13–5.
13. CDC. Immunization of health-care personnel recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(No. RR-7):1-45.
14. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months—Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1424–6.
15. CDC. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep 2011;60;1279–80.
16. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older — Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012;61;468-70.
17. CDC. Updated Recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women — Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013;62;131-5.
18. Food and Drug Administration. Product approval information – licensing action, approval letter: Adacel. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research;2014. Available at http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm392016.htm.
19. Liang J, Wallace G, Mootrey G. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR Morb Mortal Wkly Rep 2015;64:948-9.